WO2005009970A1 - An improved process for the preparation of gatifloxacin - Google Patents

An improved process for the preparation of gatifloxacin Download PDF

Info

Publication number
WO2005009970A1
WO2005009970A1 PCT/IN2004/000221 IN2004000221W WO2005009970A1 WO 2005009970 A1 WO2005009970 A1 WO 2005009970A1 IN 2004000221 W IN2004000221 W IN 2004000221W WO 2005009970 A1 WO2005009970 A1 WO 2005009970A1
Authority
WO
WIPO (PCT)
Prior art keywords
dihydro
oxo
cyclopropyl
methoxy
gatifloxacin
Prior art date
Application number
PCT/IN2004/000221
Other languages
French (fr)
Inventor
Satyanarayana Chava
Seeta Ramanjaneyulu Gorantala
Venkata Sunil Kumar Indukuri
Original Assignee
Matrix Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matrix Laboratories Ltd filed Critical Matrix Laboratories Ltd
Publication of WO2005009970A1 publication Critical patent/WO2005009970A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • the present invention relates to a process for the preparation of Gatifloxacin and its pharmaceutically acceptable salts and hydrates.-
  • Gatifloxacin chemically l-Cyclopropyl-6-fluoro-7- (3-me hyl piperazin-1-yl) -8-methoxy-4-oxo-l, 4-dihydro-3-quinoline carboxylic acid, is represented by the following formula
  • Gatifloxacin is a broad-spectrum fluoroquinolone antibiotic, which is disclosed in US Patent No. 5,043,450 as hemihydrate.
  • US Patent No. 4,980,470 discloses the method for ⁇ preparation of Gatifloxacin by condensation of l-Cyclopropyl-6, 7- difluoro-8-methoxy-4-oxo-l, 4-dihydro-3-quinoline carboxylic acid with 2-methylpiperazine in anhydrous DMSO followed by column chromatographic purification and crystallization with methanol.
  • European Patent No EP 464,823 discloses a method for the preparation of Gatifloxacin by condensation of 2-methyl piperazine with (l-Cyclopropyl-6, 7-difluoro-8-methoxy-4-oxo-l, 4-dihydro-3- quinoline carboxylic acid-0 3 ,0 4 ) bis (acetate-O) -borate followed by hydrolysis with triethylamine and crystallization with ethanol.
  • US patent No 5,880,283 discloses Gatifloxacin sesquihydrate and a process for its preparation by treating Gatifloxacin hemihydrate with water.
  • US patent Application No 2002/0052379 discloses several hydrates and claims Gatifloxacin pentahydrate.
  • Gatifloxacin crystals upon treating with hydrochloric acid in ethanol give Gatifloxacin hydrochloride in the overall yield of 40%.
  • the quality of Gatifloxacin or its hydrochloride salt was not disclosed.
  • the above method involves the exhaustive work-up resulting in exposure of Gatifloxacin to high temperature thereby enhancing the possibilities of its degradation, use of diethyl ether, which is highly inflammable solvent.
  • the main object of the present invention is to provide a process for the preparation of high pure Gatifloxacin hemihydrate.
  • Another object of the invention is to provide a process for the preparation of Gatifloxacin without involving the exhaustive work-up .
  • Yet another object of the invention is to provide a process for the purification of l-cyclopropyl-6fluoro-7 (3-methyl piperazin-1-yl) -8-methoxy-4-oxo-l, 4-dihydro-3-quinoline carboxylate boron difluoride chelate.
  • the present invention relates to a method for the preparation of Gatifloxacin hemihydrate from Ethyl-1- Cyclopropyl-6, 7-difluoro-8-methoxy-4-oxo-l, 4-dihydro-3-quinoline carboxylate through boron difluoride chelate.
  • Ethyl-1-cyclopropyl- 6, 7-difluoro-8-methoxy-4-oxo-l, 4-dihydro-3-quinoline carboxylate is reacted with aqueous hydrofluoroboric acid followed by condensation with 2-methyl piperazine in polar organic solvent resulting in an intermediate l-Cyclopropyl-7- (3-methyl piperazin-1- yl).
  • Gatifloxacin may needs purification to yield high purity product. However to obtain directly high purity Gatifloxacin it is desirable to isolate the intermediate by cooling to low temperatures . Treating with an alcohol or mixture of alcohols purifies this intermediate. The purified condensed chelate in aqueous ethanol on hydrolysis with triethylamine followed by crystallization in ethanol gives Gatifloxacin hemihydrate with high purity.
  • Fig . 1 X-ray diffraction pattern of Gatifloxacin sesquihydrate
  • Fig . 2 FTIR spectrum of Gatifloxacin sesquihydrate
  • Fig . 3 FTIR spectrum of Gatifloxacin hemihydrate
  • Fig. 4 X-ray diffraction pattern of Gatifloxacin hemihydrate
  • Gatifloxacin hemihydrate The prepared Gatifloxacin is in the form of hemihydrate, and it is confirmed by its characteristic X-ray diffraction pattern and IR spectrum. The.
  • condensation of l-Cyclopropyl-6, 7-diflut>ro-8-methoxy-4-oxo-l, 4-dihydro-3- quinoline carboxylic acid boron difluoride chelate with molar excess 2-methyl piperazine is carried out in a organic solvent (s) such as acetonitrile, methylene chloride, ethylene chloride, methyl acetate, N-methyl-2-pyrrolidinone,.
  • organic solvent such as acetonitrile, methylene chloride, ethylene chloride, methyl acetate, N-methyl-2-pyrrolidinone,.
  • methyl isobutyl ketone ethylene glycol dimethyl ether (mono gly e) , diethylene glycol dimethyl ether (diglyme) , more selectively acetonitrile at temperature about of 30°C - 35°C and mixing for about 4 to about 8 hrs .
  • reaction mass Cooling the reaction mass to low temperature preferably below 0°C and more preferably to about -10°C to about -5°C followed by isolation of the l-Cycloprdpy.1-7- (3-methylpiperazin-l-yl) -6-fluoro-8-methoxy-4- oxo-1, 4-dihydro-3-quinoline carboxylic acid boron difluoride chelate .However the intermediate need not be isolated and can be further hydrolyzed by treating with triethyl amine to yield Gatifloxacin.
  • the impurities from l-Cyclopropyl-7- (3-methylpiperazin-l-yl) - 6-fluoro-8-methoxy-4 ⁇ oxo-l, 4-dihydro-3-quinolinecarboxylic acid boron difluoride chelate are separated by treating with an alcohol or mixture of alcohols such as methanol, ethanol, n-propanol, iso- propanol, butanol preferably methanol at selective temperature preferably at about 15°C to about 45°C for about 1 to about 4 hrs, followed by cooling the reaction mixture to low temperature preferably to 15°C, to 25°C.
  • an alcohol or mixture of alcohols such as methanol, ethanol, n-propanol, iso- propanol, butanol preferably methanol at selective temperature preferably at about 15°C to about 45°C for about 1 to about 4 hrs, followed by cooling the reaction mixture to low temperature preferably to 15°C, to 25°C.
  • the intermediate l-Cyclopropyl-7- (3-methylpiperazin-l- yl) -6-fluoro-8-methoxy-4-oxo-l, 4-dihydro-3-quinoline carboxylic acid boron difluoride_ chelate is treated (without separation, isolation or purification) with • triethylamine to yield Gatifloxacin, hich requires purification to yield pure Gatifloxacin.
  • the -invention can be further illustrated by the below non-limiting examples .
  • Stage-1 Preparation of l-cyclopropyl-6, 7-di luoro-8-methoxy-4-oxo- 1, 4-dihydro-3-quinoline carboxylic acid boron difluoride chelate.
  • Ethyl-l-cyclopropyl-6, 7-difluoro-8-methoxy-4-oxo-l, -dihydro-3- quin ⁇ line carboxylate (100g) is suspended in ,40%aq..hydrofluoroboric acid -(1000 ml).
  • Temperature of • the reaction mass is raised and maintained at 95°C to 100°C for 5hrs followed by cooling to 30°C - 35°C.
  • the condensed chelate (100 g) prepared as above is suspended in methanol (1500 ml), maintained at 40°C - 45°C for 30 min.
  • the reaction mass is gradually cooled, maintained for 1 hr at -5°C to 0°C.
  • the product is filtered, washed with methanol (50 ml) and dried at 45°C - 50°C to constant weight. Dry weight of the product: 80.0 g (Yield: 80.0 %)
  • the pure condensed chelate (100.0 g) prepared as above in stage-2 is suspended in 20% aq. ethanol (1000 ml) , the temperature is raised and maintained at 75°C to 80°C for 2 hrs.
  • the reaction mass is cooled, filtered to remove insolubles, distilled under vacuum to remove solvent.
  • Fresh ethanol (200 ml) is added and solvent is removed under vacuum at temperature below 50°C.
  • Ethanol (200 ml) is added to the residue and gradually cooled to -10°C to -5°C.
  • the reaction mass is mixed at -10°C to -5°C for 1 hr and then filtered.
  • the wet cake is washed with ethanol (25 ml) and dried at 45°C - 50°C to constant weight.
  • the dry weight of the Gatifloxacin is 83.3 g (Yield: 91.7 %)
  • Stage-1 Preparation of l-cyclopropyl-6, 7-difluoro-8-methoxy-4- oxo-1, 4-dihydro-3-quinoline carboxylic acid boron difluoride chelate.
  • Ethyll-cyclopropyl-6, 7-difluoro-8-methoxy-4-oxo-l, 4-dihydro-3- quinoline carboxylate (lOOg) is suspended in 40% aq. hydrofluoroboric acid (1000 ml) . Temperature of the reaction mass is raised and maintained at 95°C to 100°C for 5 hrs followed by cooling to 30°C - 35°C. 400 ml DM water is added, maintained at 25°C - 30°C for 2hrs . The product is filtered, washed with DM water (500 ml) and dried at 40°C - 45°C to constant weight. The dry wt is 102.5 g (Yield: 96.6 %)
  • the boron difluoride chelate derivative (100 g) prepared as above in stage-1 is suspended in acetonitrile (800 ml) , 2-methyl piperazine (44 g, 1.5 mole equiv.) is added and mixed for 15 min to obtain a clear solution.
  • the reaction mass is maintained at 30°C - 35°C for 12 hrs. Removed the solvent by vacuum distillation. 20% Aq. ethanol (1000 ml) is added, raised the temperature and maintained at 75°C to 80°C for 2 hrs.
  • the reaction mass is cooled, filtered to remove insolubles.
  • the filtrate is distilled under vacuum to remove solvent completely.
  • Fresh ethanol (250 ml) is added and distilled under vacuum at temperature below 50°C.
  • Fresh Ethanol (250 ml) is added to the residue and gradually cooled to -10°C to -5°C.
  • the reaction mass is maintained at -10°C to -5°C for 1 hr and filtered.
  • the wet cake is washed with ethanol (30 ml) and dried at 45°C - 50°C to constant weight.
  • the dry weight of the Gatifloxacin is 73.5 g (Yield: 65.4 %)
  • the dry weight of the pure Gatifloxacin is 56.0 g (Yield: 70.0 %)

Abstract

The present invention relates to a process for the preparation of Gatifloxacin by reacting ethvl 1-cyclopropyl-6,7-difluoro-8­ methoxy-4-oxo-1,4-dihydro-3-quinoline carboxylate with aqueous hydrofluoroboric acid followed by condensation with 2-methyl piperazine in polar organic solvent resulting in an intermediate Cyclopropyl-7-(3-methylpiperazin-1-yl)-6-fluoro-8-methoxy-4-oxo­ 1,4-dihydro-3-quinoline carboxylic acid boron difluoride chelate which upon hydrolysis yields Gatifloxacin.

Description

An improved process for the preparation of Gati loxacin:
The present invention relates to a process for the preparation of Gatifloxacin and its pharmaceutically acceptable salts and hydrates.-
Gatifloxacin, chemically l-Cyclopropyl-6-fluoro-7- (3-me hyl piperazin-1-yl) -8-methoxy-4-oxo-l, 4-dihydro-3-quinoline carboxylic acid, is represented by the following formula
Figure imgf000003_0001
GATIFLOXACIN
Gatifloxacin is a broad-spectrum fluoroquinolone antibiotic, which is disclosed in US Patent No. 5,043,450 as hemihydrate. For the preparation of Gatifloxacin there are few more methods reported in literature. US Patent No. 4,980,470 discloses the method for ι preparation of Gatifloxacin by condensation of l-Cyclopropyl-6, 7- difluoro-8-methoxy-4-oxo-l, 4-dihydro-3-quinoline carboxylic acid with 2-methylpiperazine in anhydrous DMSO followed by column chromatographic purification and crystallization with methanol.
European Patent No EP 464,823 discloses a method for the preparation of Gatifloxacin by condensation of 2-methyl piperazine with (l-Cyclopropyl-6, 7-difluoro-8-methoxy-4-oxo-l, 4-dihydro-3- quinoline carboxylic acid-03,04) bis (acetate-O) -borate followed by hydrolysis with triethylamine and crystallization with ethanol. US patent No 5,880,283 discloses Gatifloxacin sesquihydrate and a process for its preparation by treating Gatifloxacin hemihydrate with water. US patent Application No 2002/0052379 discloses several hydrates and claims Gatifloxacin pentahydrate. It also discloses the process for preparing Gatifloxacin pentahydrate by water equilibration of Gatifloxacin sesquihydrate or Gatifloxacin hemihydrate. US Patent No 4,997,943 discloses the preparation of Gatifloxacin, which comprises : • treating ethyl l-cyclopropyl-6, 7-difluoro-8-methoxy-4-oxo-l, 4- dihydro-3-quinoline carboxylate with hydro luoroboric acid to give boron difluoride chelate derivative • mixing the chelate derivative with 2-methyl piperazine (4.0 mol equiv.) in DMSO at room temperature for overnight • , evaporating the excess 2-methylpiperazine along with DMSO by vacuum • washing the residue with diethyl ether • separating the condensed chelate compound. • dissolving the condensed chelate in a mixture of 80% aqueous ethanol, triethyl a ine and maintaining at reflux temperature for 4 hrs • cooling the reaction mass to RT and separating the insolubles by filtration, • concentrating the filtrate under vacuum to separate the crystals and washing with ethanol.
Gatifloxacin crystals upon treating with hydrochloric acid in ethanol give Gatifloxacin hydrochloride in the overall yield of 40%. The quality of Gatifloxacin or its hydrochloride salt was not disclosed. The above method involves the exhaustive work-up resulting in exposure of Gatifloxacin to high temperature thereby enhancing the possibilities of its degradation, use of diethyl ether, which is highly inflammable solvent. Further it involves the use of a large molar excess of 2-methyl piperazine vis-a-vis 1-cyclopropyl- 6, 7-difluoro-8-methoxy-4-oxo-l, 4-dihydro-3~quinoline ' carboxylic acid / or its boron difluoride chelate i.e. 4 : 1 there by increasing the consumptions of 2-methylpiperazine leading to the formation of impurities. It also involves the conversion to hydrochloride without isolation of Gatifloxacin. In US patent. No 4,980,470 the purification of crude Gatifloxacin involves the use of column chro atography, with the handling of solvents in very high volumes.
It has been a long felt need of the industry to provide commercially feasible and cost effective processes to yield high purity Gatifloxacin.
The main object of the present invention is to provide a process for the preparation of high pure Gatifloxacin hemihydrate.
Another object of the invention is to provide a process for the preparation of Gatifloxacin without involving the exhaustive work-up . Yet another object of the invention is to provide a process for the purification of l-cyclopropyl-6fluoro-7 (3-methyl piperazin-1-yl) -8-methoxy-4-oxo-l, 4-dihydro-3-quinoline carboxylate boron difluoride chelate. Accordingly, the present invention relates to a method for the preparation of Gatifloxacin hemihydrate from Ethyl-1- Cyclopropyl-6, 7-difluoro-8-methoxy-4-oxo-l, 4-dihydro-3-quinoline carboxylate through boron difluoride chelate. Ethyl-1-cyclopropyl- 6, 7-difluoro-8-methoxy-4-oxo-l, 4-dihydro-3-quinoline carboxylate is reacted with aqueous hydrofluoroboric acid followed by condensation with 2-methyl piperazine in polar organic solvent resulting in an intermediate l-Cyclopropyl-7- (3-methyl piperazin-1- yl). -6-fluoro-8-methoxy-4-oxo-l, 4-dihydro-3-quinoline carboxylic acid boron difluoride chelate. This intermediate may be further hydrolyzed to yield Gatifloxacin. Gatifloxacin so obtained may needs purification to yield high purity product. However to obtain directly high purity Gatifloxacin it is desirable to isolate the intermediate by cooling to low temperatures . Treating with an alcohol or mixture of alcohols purifies this intermediate. The purified condensed chelate in aqueous ethanol on hydrolysis with triethylamine followed by crystallization in ethanol gives Gatifloxacin hemihydrate with high purity.
STAGE - I:
Figure imgf000006_0001
Ethyl l-cyclopropyl-6,7-difluoro-8-met oxy l-Cycloproρyl-6, 7-difluoro-8-methoxy -4-oxo-l, -dihydro-3-quinoline -4-oxo-l, 4-dihydro-3-quinoline carboxylate carboxylic acid boron difluoride chelate
STAGE - II :
Figure imgf000007_0001
l-Cycloprop l-7- ( 3-methylpiperazin-l-yl.
Figure imgf000007_0002
6-fluoro~8-methoxy-4-oxo-l , 4-dihydro-3- carboxylicacid borondifluoride chelate quinoline carboxylicacid borondifluoride chelate
STAGE -III :
Figure imgf000007_0003
l-Cyclopropyl-7- (3- ethylpiperaz.in-l-yl . GATIFLOXACIN
-6-fluoro-8-methoxy-4-oxo-l , 4-dihydro-3- quinoline carboxylicacid borondifluoride chelate
Brief description of the drawings : Fig . 1 : X-ray diffraction pattern of Gatifloxacin sesquihydrate Fig . 2 : FTIR spectrum of Gatifloxacin sesquihydrate Fig . 3 : FTIR spectrum of Gatifloxacin hemihydrate Fig. 4 : X-ray diffraction pattern of Gatifloxacin hemihydrate
The essential features of the present invention comprising steps :
Reacting Ethyl l-cyclopropyl-6, 7-difluoro-8-methoxy-4-oxo-lf 4- dihydro- 3-quinoline carboxylate with aq. hydrofluoroboricacid ■ Isolating l-Cyclopropyl-6, 7-difluoro-8~methoxy-4-oxo-l, 4- dihydro-3-quinoline carboxylic acid boron difluoride chelate by addition of water .followed by cooling " Condensing l-Cyclopropyl-6, 7-difluoro-8-methoxy-4-oxo-l, - dihydro-3-quinoline carboxylic acid boron difluoride chelate with 2-methyl piperazine in organic solvent (s) ■ Cooling the reaction mass to low temperature to crystallize the intermediate l-Cyclopropyl-7- (3-methylpiperazin-l-yl) -6- fluoro-8-methoxy-4-oxo-l, 4-dihydro-3-quinoline carboxylic acid boron difluoride chelate ■ Hydrolyzing l-Cyclopropyl-7- (3-methylpiperazin-l-yl) -6-fluoro- 8-methoxy-4-oxo-l, 4-dihydro-3-quinoline carboxylic acid boron difluoride chelate by treating with triethyl amine ■ Optionally isolating the intermediate l-Cyclopropyl-7- (3- methylpiperazin-1-yl) -6-fluoro-8-methoxy-4-oxo-l, 4-dihydro-3- quinoline carboxylic acid boron difluoride chelate ■ Separating the impurities from l-Cyclopropyl-7- (3- methylpiperazin-1-yl) -6-fluoro-8-methoxy-4-oxo-l, 4-dihydro-3- quinoline carboxylic acid boron difluoride chelate by treating with alcohol at selective temperature ■ Reactingl-Cyclopropyl-7- (3-methylpiperazin-l-yl) -6-fluoro-8- methoxy-4-oxo-l> -dihydro-3-quinoline carboxylic acid boron difluoride chelate in aq. ethanol with triethylamine ■ Removing aq. ethanol under vacuum followed by adding fresh ethanol ■ Crystallizing the crude Gatifloxacin ■ Treating the crystallized crude Gatifloxacin with hot methanol to give Gatifloxacin hemihydrate The prepared Gatifloxacin is in the form of hemihydrate, and it is confirmed by its characteristic X-ray diffraction pattern and IR spectrum. The. starting materials Ethyl l-cyclopropyl-6, 7-difluoro-8- methoxy-4-oxo-l, 4-dihydro-3-quinoline carboxylate and 1- Cyclopropyl-6, 7-difluoro-8-methoxy-4-oxo-l, 4-dihydro-3-quinoline carboxylic acid boron difluoride chelate are prepared by the literature reported methods .
Thus in accordance to the present invention condensation of l-Cyclopropyl-6, 7-diflut>ro-8-methoxy-4-oxo-l, 4-dihydro-3- quinoline carboxylic acid boron difluoride chelate with molar excess 2-methyl piperazine is carried out in a organic solvent (s) such as acetonitrile, methylene chloride, ethylene chloride, methyl acetate, N-methyl-2-pyrrolidinone,. methyl isobutyl ketone, ethylene glycol dimethyl ether (mono gly e) , diethylene glycol dimethyl ether (diglyme) , more selectively acetonitrile at temperature about of 30°C - 35°C and mixing for about 4 to about 8 hrs . Cooling the reaction mass to low temperature preferably below 0°C and more preferably to about -10°C to about -5°C followed by isolation of the l-Cycloprdpy.1-7- (3-methylpiperazin-l-yl) -6-fluoro-8-methoxy-4- oxo-1, 4-dihydro-3-quinoline carboxylic acid boron difluoride chelate .However the intermediate need not be isolated and can be further hydrolyzed by treating with triethyl amine to yield Gatifloxacin.
The impurities from l-Cyclopropyl-7- (3-methylpiperazin-l-yl) - 6-fluoro-8-methoxy-4~oxo-l, 4-dihydro-3-quinolinecarboxylic acid boron difluoride chelate are separated by treating with an alcohol or mixture of alcohols such as methanol, ethanol, n-propanol, iso- propanol, butanol preferably methanol at selective temperature preferably at about 15°C to about 45°C for about 1 to about 4 hrs, followed by cooling the reaction mixture to low temperature preferably to 15°C, to 25°C. Treating the suspension of 'the 1- Cyclopropyl-7- (3-methylpiperazin-l-yl) -6-fluoro-8-methoxy-4-oxo- 1, 4-dihydro-3-quinoline carboxylic acid boron difluoride chelate with triethylamine in aqueous ethanol or in acetonitrile, at higher temperatures preferably at reflux temperature of the solvent for about 2 to 6 hrs, followed by removing the solvent and then adding fresh solvent, mixing and cooling to low temperatures preferably to below 0°C, more preferably to about -15°C to about -5°C to give the crude Gatifloxacin. Dissolving the. crude Gatifloxacin in methanol at .hot condition, removing insolubles if any, cooling the clear filtrate to low temperatures preferably • to about -10°C to about 0°C followed by isolation and drying affords Gatifloxacin hemihydrate.
It may be noted that in the preferred embodiment of this invention the intermediate l-Cyclopropyl-7- (3-methylpiperazin-l- yl) -6-fluoro-8-methoxy-4-oxo-l, - dihydro-3-quinoline carboxylic acid boron difluoride chelate is separated, purified and further treated- to yield pure Gatifloxacin. In another embodiment of the invention the intermediate l-Cyclopropyl-7- (3-methylpiperazin-l- yl) -6-fluoro-8-methoxy-4-oxo-l, 4-dihydro-3-quinoline carboxylic acid boron difluoride_ chelate is treated (without separation, isolation or purification) with • triethylamine to yield Gatifloxacin, hich requires purification to yield pure Gatifloxacin.
The -invention can be further illustrated by the below non-limiting examples .
Example-I: Preparation of Gatifloxacin • with isolation of intermediate (boron difluoride chelate derivative)
Stage-1: Preparation of l-cyclopropyl-6, 7-di luoro-8-methoxy-4-oxo- 1, 4-dihydro-3-quinoline carboxylic acid boron difluoride chelate. Ethyl-l-cyclopropyl-6, 7-difluoro-8-methoxy-4-oxo-l, -dihydro-3- quinόline carboxylate (100g)is suspended in ,40%aq..hydrofluoroboric acid -(1000 ml). Temperature of • the reaction mass is raised and maintained at 95°C to 100°C for 5hrs followed by cooling to 30°C - 35°C. Water (400 ml) is added and maintained at 25°C - 30°C for 2hrs . Product is filtered, washed with water (500 ml) and dried at 40°C - 45°C to constant weight. Dry weight of the product: 101.6 g (Yield: 95.8 %)
Stage-2: Preparation of 1- Cyclopropyl-7- (3-methylpiperazin-l-yl) - 6-fluoro-8-methoxy-4-oxo-l, -dihydro-3-quinoline carboxylic acid boron difluoride chelate
100 g of Boron difluoride chelate derivative prepared as above in stage-1 is suspended in acetonitrile (800 ml) , to that 2-methyl piperazine (44.0 g, 1.5 mole equiv.) is added and mixed for 15 min to obtain a clear solution. The reaction mass is maintained at 30°C - 35°C for 12 hrs followed by cooling to -10°C to -5°C. The reaction mass is maintained at -10°C to -5°C for 1 hr. The product is filtered and dried at 45°C - 50°C to constant weight. Dry weight of the product: 116.0 g (Yield: 93.9 %) .
The condensed chelate (100 g) prepared as above is suspended in methanol (1500 ml), maintained at 40°C - 45°C for 30 min. The reaction mass is gradually cooled, maintained for 1 hr at -5°C to 0°C. The product is filtered, washed with methanol (50 ml) and dried at 45°C - 50°C to constant weight. Dry weight of the product: 80.0 g (Yield: 80.0 %)
Stage -3: Preparation of Gatifloxacin (Crude)
The pure condensed chelate (100.0 g) prepared as above in stage-2 is suspended in 20% aq. ethanol (1000 ml) , the temperature is raised and maintained at 75°C to 80°C for 2 hrs. The reaction mass is cooled, filtered to remove insolubles, distilled under vacuum to remove solvent. Fresh ethanol (200 ml) is added and solvent is removed under vacuum at temperature below 50°C. Ethanol (200 ml) is added to the residue and gradually cooled to -10°C to -5°C. The reaction mass is mixed at -10°C to -5°C for 1 hr and then filtered. The wet cake is washed with ethanol (25 ml) and dried at 45°C - 50°C to constant weight.
The dry weight of the Gatifloxacin is 83.3 g (Yield: 91.7 %)
Stage- 4: Purification of crude Gatifloxacin
Crude Gatifloxacin (100.0 g) prepared as above in stage-3 is suspended in methanol (4000 ml), the temperature is raised and maintained at 60°C to 65°C for 20 min. to get a clear solution. Activated carbon (5 g) is added, maintained for 30 min and the solution is filtered. The filtrate is concentrated to one third of its original volume under vacuum at temperature below 40°C. The reaction mass is gradually cooled and maintained at -10°C to -5°C for 2 hrs. The product is filtered, washed with methanol (50 ml) and dried at 45°C - 50°C to constant weight. The dry weight of the pure Gatifloxacin is 76.0 g (Yield: 76.0 %)
Example-II: Preparation of Gatifloxacin without isolation of intermediate (boron difluoride chelate derivative)
Stage-1: Preparation of l-cyclopropyl-6, 7-difluoro-8-methoxy-4- oxo-1, 4-dihydro-3-quinoline carboxylic acid boron difluoride chelate.
Ethyll-cyclopropyl-6, 7-difluoro-8-methoxy-4-oxo-l, 4-dihydro-3- quinoline carboxylate (lOOg) is suspended in 40% aq. hydrofluoroboric acid (1000 ml) . Temperature of the reaction mass is raised and maintained at 95°C to 100°C for 5 hrs followed by cooling to 30°C - 35°C. 400 ml DM water is added, maintained at 25°C - 30°C for 2hrs . The product is filtered, washed with DM water (500 ml) and dried at 40°C - 45°C to constant weight. The dry wt is 102.5 g (Yield: 96.6 %)
Stage - 2: Preparation of Gatifloxacin (Crude)
The boron difluoride chelate derivative (100 g) prepared as above in stage-1 is suspended in acetonitrile (800 ml) , 2-methyl piperazine (44 g, 1.5 mole equiv.) is added and mixed for 15 min to obtain a clear solution. The reaction mass is maintained at 30°C - 35°C for 12 hrs. Removed the solvent by vacuum distillation. 20% Aq. ethanol (1000 ml) is added, raised the temperature and maintained at 75°C to 80°C for 2 hrs. The reaction mass is cooled, filtered to remove insolubles. The filtrate is distilled under vacuum to remove solvent completely. Fresh ethanol (250 ml) is added and distilled under vacuum at temperature below 50°C. Fresh Ethanol (250 ml) is added to the residue and gradually cooled to -10°C to -5°C. The reaction mass is maintained at -10°C to -5°C for 1 hr and filtered. The wet cake is washed with ethanol (30 ml) and dried at 45°C - 50°C to constant weight.
The dry weight of the Gatifloxacin is 73.5 g (Yield: 65.4 %)
Stage -3: Purification of crude Gatifloxacin
Crude Gatifloxacin (80.0 g) prepared as above in stage-2 is suspended in methanol (2000 ml) , the temperature is raised and maintained at 60°C to 65°C for 20 min. to get a clear solution. The reaction mixture is filtered. The filtrate is gradually cooled and maintained at -10°C to -5°C for 2 hrs. The product is filtered, washed with methanol (50 ml) and dried at 45°C - 50°C to constant weight.
The dry weight of the pure Gatifloxacin is 56.0 g (Yield: 70.0 %)

Claims

We claim:
1. !A process for the preparation of Gatifloxacin comprising steps of:
Reacting Ethyl l-cyclopropyl-6, 7-difluoro-8-methoxy-4-oxo-l, 4- dihydro- 3-quinoline carboxylate with aq. hydrofluoroboricacid Isolating l-Cyclopropyl-6, 7-difluoro-8-methoxy-4-oxo-l, - dihydro-3-quinoline carboxylic acid boron difluoride chelate by addition of water followed by cooling Condensing l-Cyclopropyl-6, 7-difluoro-8-methoxy-4-oxo-l, 4- dihydro-3-quinoline carboxylic acid boron difluoride chelate with 2-methyl piperazine in organic solvent (s) Cooling the reaction mass to low temperature to crystallize the intermediate l-Cyclopropyl-7- (3-methylpiperazin-l-yl) -6- fluoro-8-methoxy-4-oxo-l, 4-dihydro-3-quinoline carboxylic acid boron difluoride chelate Hydrolyzing l-Cyclopropyl-7- (3-methylpiperazin-l-yl) -6-fluoro- 8~methoxy-4-oxo-l, -dihydro-3-quinoline carboxylic acid boron difluoride chelate by treating with triethyl amine Optionally- isolating the intermediate l-Cyclopropyl-7- (3- methylpiperazin—1-yl) -6- luoro-8-methoχy- -oxo-l, 4-dihydro-3- quinoline carboxylic acid boron difluoride chelate Separating the impurities from l-Cyclopropyl-7- (3- methylpiperazin-l-yl)-6-fluoro-8-methoxy-4~oxo-l, 4-dihydro-3- quinoline carboxylic acid boron difluoride chelate by treating with alcohol at selective temperature Reactingl-Cyclopropyl-7- (3-methylpiperazin-l-yl) -6-fluoro-8- methoxy-4-oxo-l, 4-dihydro-3-quinoline carboxylic acid boron difluoride chelate in aq. ethanol with triethylamine Removing aq. ethanol under vacuum followed by adding fresh ethanol ■ Crystallizing the crude Gatifloxacin ■ Treating the crystallized crude Gatifloxacin with hot methanol
2. A process as claimed in claim 1, wherein the organic solvent (s) is acetonitrile or ethanol or methylene chloride or ethylene chloride or methyl isobutyl ketone or methyl acetate or N-methyl- 2-pyrrolidinone or mono glyme or di glyme
3. A process as claimed in claims 1 & 2, wherein the more preferred organic solvent is acetonitrile
4. A process as claimed in claim 1, wherein the isolation of the intermediate l-Cyclopropyl-7- (3-methylpiperazin-l-yl) -6-fluoro-8- methoxy-4-oxo-l, -dihydro-3-quinoline carboxylicacid boron difluoride chelate by cooling the reaction mass to temperature below 10°C preferably -10°C to 0°C
5. A process as claimed in claim 1, wherein the alcohol is methanol or Ethanol or propanol or iso-propanol or butanol or mixtures thereof
6. A process as claimed in claim 1 & 5 wherein the preferred alcohol is Methanol
7. A process as claimed in claim 1, wherein the Gatifloxacin is crystallized at temperature below 10°C, preferably -10°C to 0°C
PCT/IN2004/000221 2003-07-28 2004-07-23 An improved process for the preparation of gatifloxacin WO2005009970A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN603/CHE/2003 2003-07-28
IN603CH2003 2003-07-28

Publications (1)

Publication Number Publication Date
WO2005009970A1 true WO2005009970A1 (en) 2005-02-03

Family

ID=34090475

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2004/000221 WO2005009970A1 (en) 2003-07-28 2004-07-23 An improved process for the preparation of gatifloxacin

Country Status (1)

Country Link
WO (1) WO2005009970A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008073444A3 (en) * 2006-12-12 2009-03-12 Univ Johns Hopkins Phou (perf), a persistence switch involved in persister formation as a drug target for persister bacteria
CN102351843A (en) * 2011-08-18 2012-02-15 张家口市格瑞高新技术有限公司 Synthesis method of 2-methyl piperazine lomefloxacin
CN101659654B (en) * 2008-08-28 2013-11-06 四川科伦药物研究有限公司 2-Methylpiperazine fluoroquinolone compound and preparation method and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997943A (en) * 1986-03-31 1991-03-05 Sankyo Company Limited Quinoline-3-carboxylic acid derivatives
EP0464823A1 (en) * 1990-07-06 1992-01-08 Kyorin Pharmaceutical Co., Ltd. (6,7-Substituted-8-alkoxy-1-cyclopropyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid-O3,O4)bis(acyloxy-O)borates and the salts thereof, and methods for their manufacture

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997943A (en) * 1986-03-31 1991-03-05 Sankyo Company Limited Quinoline-3-carboxylic acid derivatives
EP0464823A1 (en) * 1990-07-06 1992-01-08 Kyorin Pharmaceutical Co., Ltd. (6,7-Substituted-8-alkoxy-1-cyclopropyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid-O3,O4)bis(acyloxy-O)borates and the salts thereof, and methods for their manufacture

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008073444A3 (en) * 2006-12-12 2009-03-12 Univ Johns Hopkins Phou (perf), a persistence switch involved in persister formation as a drug target for persister bacteria
CN101659654B (en) * 2008-08-28 2013-11-06 四川科伦药物研究有限公司 2-Methylpiperazine fluoroquinolone compound and preparation method and application thereof
CN102351843A (en) * 2011-08-18 2012-02-15 张家口市格瑞高新技术有限公司 Synthesis method of 2-methyl piperazine lomefloxacin

Similar Documents

Publication Publication Date Title
US8049009B2 (en) Process for the preparation of Tenofovir
JP5774732B2 (en) Method for the synthesis of moxifloxacin hydrochloride
EP2951158B1 (en) Process for the preparation of ivacaftor and solvates thereof
CA2594690C (en) Salts of aripiprazole
ES2372414T3 (en) PURIFICATION PROCEDURE OF MONTELUKAST AND ITS SALTS OF AMINAS.
US20060264635A1 (en) Process for the preparation of moxifloxacin hydrochloride
CN103930414A (en) 7-{(3S,4S)-3-[(cyclopropylamino)methyl]-4-fluoropyrrolidine-1-yl}-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid crystal
WO2007100387A2 (en) Process for preparing tadalafil
CN111233833A (en) Preparation method of deuterated macrocyclic compound
US20110212990A1 (en) Novel polymorph of moxifloxacin hydrochloride
WO2009133468A1 (en) Improved process for preparing quinoline-3-carboxamide derivatives
WO2005009970A1 (en) An improved process for the preparation of gatifloxacin
KR100740950B1 (en) Crystal modification B of 8-cyano-1-cyclopropyl-7-1S,6S-2,8-diazabicyclo[4.3.0]nonan-8-yl-6-fluoro-1,4-dihydro-4-oxo-3-quinoline carboxylic acid
EP2178864B1 (en) Process for the preparation of alfuzosin hydrochloride
US20080146809A1 (en) Process for the Preparation of Novel Amorphous Montelukast Sodium
US20130085304A1 (en) Processes for preparation of polymorphic forms of lacosamide
US7781585B2 (en) Crystalline forms of Gatifloxacin
WO2001004094A1 (en) Processes for the preparation of ipidacrine or ipidacrine hydrochloride hydrate
WO2009087667A2 (en) A new method for preparation of zopiclone and its polymorphs
US20070032505A1 (en) Crystalline form of gatifloxacin
KR20040097930A (en) For the synthesis of n-methyl-n-phenylaminoacrolein
WO2015049623A1 (en) Crystalline abacavir hydrochloride monohydrate and process for its preparation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase